CVRx, Inc.
CVRx (Nasdaq: CVRX) is a commercial-stage medical device company that develops, manufactures and commercializes neuromodulation therapies for cardiovascular disease. Its principal product, Barostim, is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, providing Baroreflex… From the company’s description.
Over the twelve months to Sep 30, 2026, CVRx, Inc. reported revenue of $60.33M, up 7.8% from a year earlier, and a net loss of $53.26M. Its operating margin was −81.9%, and operations used $41.65M in cash. In fiscal 2025, it reported revenue of $56.65M, up 10.4% from fiscal 2024, and a net loss of $53.31M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CVRx, Inc. does
In the company’s own words
CVRx (Nasdaq: CVRX) is a commercial-stage medical device company that develops, manufactures and commercializes neuromodulation therapies for cardiovascular disease. Its principal product, Barostim, is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, providing Baroreflex Activation Therapy to improve symptoms in eligible patients with heart failure with reduced ejection fraction. The therapy is designed to complement guideline-directed medical treatment, and the device is implanted through a minimally invasive procedure and managed wirelessly by clinicians. CVRx sells primarily to hospitals, using a direct sales organization in the United States and Germany and distributors in Austria, Spain and other European countries; its commercial efforts engage cardiologists, heart failure specialists and surgeons. The company focuses its current commercial and development activities on Barostim, while investigating use in broader heart failure populations. CVRx reported revenue of $56.7 million for fiscal 2025. Its website is https://www.cvrx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MINNEAPOLIS, MN
- Fiscal year end
- December
- CIK
- 1235912
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CVRx, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CVRx, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CVRx, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CVRx, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CVRx, Inc.'s last four quarterly filings that the numbers alone won't show?”